title: Glucocorticoids in Alzheimer's disease. The story so far.
abstract: The inflammatory hypothesis of Alzheimer's disease states that specific inflammatory mechanisms, including the cytokine-driven acute-phase response, complement activation and microglial activation, contribute to neurodegeneration. If the hypothesis is correct, anti-inflammatory treatment aimed at suppression of these mechanisms could slow the rate of disease progression. Towards this goal, a multicentre trial of prednisone in Alzheimer's disease is under way and pilot studies of other anti-inflammatory regimens are being conducted.
authors.affiliation: Department of Psychiatry, Mount Sinai Medical Center, New York, New York, USA. psams@cunyvm.cuny.edu
authors.forename: P S
authors.initials: PS
authors.lastname: Aisen
authors.forename: G M
authors.initials: GM
authors.lastname: Pasinetti
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D005938:Glucocorticoids / Q000502:physiology*; D006801:Humans
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids